Taysha Gene Therapies’ (TSHA) Buy Rating Reiterated at Chardan Capital
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research report issued on Thursday,Benzinga reports. They currently have a $7.00 price target on the stock. Chardan Capital’s price target suggests a potential upside of 208.37% from the company’s current price. Several other […]
More Stories
Banco Bradesco (NYSE:BBD) Reaches New 52-Week Low – Here’s Why
Banco Bradesco S.A. (NYSE:BBD – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Monday...
Alexandria Real Estate Equities, Inc. (NYSE:ARE) Shares Sold by Teachers Retirement System of The State of Kentucky
Teachers Retirement System of The State of Kentucky cut its stake in shares of Alexandria Real Estate Equities, Inc. (NYSE:ARE...
Hagerty, Inc. (NYSE:HGTY) Sees Significant Drop in Short Interest
Hagerty, Inc. (NYSE:HGTY – Get Free Report) was the target of a large decline in short interest during the month...
Brokerages Set Rexford Industrial Realty, Inc. (NYSE:REXR) Target Price at $51.09
Shares of Rexford Industrial Realty, Inc. (NYSE:REXR – Get Free Report) have been given an average recommendation of “Hold” by...
**Funko, Inc. Elects Jason Harinstein as New Director**
On December 13, 2024, Funko, Inc. (NASDAQ: FNKO) announced the appointment of Jason Harinstein as a Class I director, following...
Barclays PLC Acquires 22,752 Shares of UGI Co. (NYSE:UGI)
Barclays PLC boosted its holdings in shares of UGI Co. (NYSE:UGI – Free Report) by 7.8% in the 3rd quarter,...